Glenmede Trust’s Pacific Biosciences PACB Stock Holding History

Glenmede Trust’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-51,153	Closed	-$502K	–	1376
2023 Q4	$502K	Buy	+51,153	New	+$418K	﹤0.01%	891
2020 Q4	–	Sell	-593	Closed	-$5K	–	1933
2020 Q3	$5K	Hold	593	–	–	﹤0.01%	2096
2020 Q2	$2K	Sell	593 -147	-20%	-$500	﹤0.01%	2256
2020 Q1	$3K	Hold	740	–	–	﹤0.01%	2801
2019 Q4	$3K	Hold	740	–	–	﹤0.01%	2801
2019 Q3	$3K	Hold	740	–	–	﹤0.01%	2780
2019 Q2	$4K	Hold	740	–	–	﹤0.01%	2699
2019 Q1	$5K	Sell	740 -187	-20%	-$1.35K	﹤0.01%	2616
2018 Q4	$6K	Buy	+927	New	+$5.87K	﹤0.01%	2479
2017 Q3	–	Sell	-202	Closed	-$1K	–	2803
2017 Q2	$1K	Hold	202	–	–	﹤0.01%	2602
2017 Q1	$1K	Hold	202	–	–	﹤0.01%	2602
2016 Q4	$0	Buy	+202	New	+$1.47K	﹤0.01%	2576
2015 Q1	–	Sell	-7,000	Closed	-$54K	–	2517
2014 Q4	$54K	Buy	+7,000	New	+$44.8K	﹤0.01%	1727

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Glenmede Trust's PACB Position: Q1 2024 in Review

Glenmede Trust sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 51,153 shares — an estimated $502K sold.

Glenmede Trust first reported a position in PACB in Q4 2014 and held it in 13 quarters. The position peaked at $502K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

Glenmede Trust reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
Glenmede Trust sold 51,153 Pacific Biosciences shares in Q1 2024, an estimated $502K.
Glenmede Trust first reported a position in Pacific Biosciences in Q4 2014 and held it in 13 quarters.
Glenmede Trust's Pacific Biosciences position peaked at $502K in Q4 2023.
268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Glenmede Trust's 13F filing for Q1 2024, filed 15 May 2024.